Merck announced on Dec. 18, 2014 that it acquired a Swiss-based, privately held biotechnology company, OncoEthix, specializing in oncology drug development. The acquisition gives Merck OTX015 , an investigational BET bromodomain inhibitor designed to treat hematological malignancies aOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.